Hawre J Jalal

List of Publications by Year in Descending Order

40 papers	781 citations	14 h-index	27 g-index
44 ext. papers	1,046 ext. citations	5.2 avg, IF	4.66 L-index

#	Paper	IF	Citations
40	Reply commentary by Jalal and Burke.. *International Journal of Drug Policy*, **2022**, 103674	5.5	0
39	Exponential growth of drug overdose poisoning and opportunities for intervention.. *Addiction*, **2022**, 117, 1200-1202	4.6	1
38	Estimating the Impact of Low Influenza Activity in 2020 on Population Immunity and Future Influenza Seasons in the United States.. *Open Forum Infectious Diseases*, **2022**, 9, ofab607	1	1
37	APCtools: Descriptive and Model-based Age-Period-Cohort Analysis. *Journal of Open Source Software*, **2022**, 7, 4056	5.2	
36	BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. *Frontiers in Physiology*, **2021**, 12, 662314	4.6	2
35	Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? ⬚ value of information analysis. *Vaccine*, **2021**, 39, 3608-3613	4.1	0
34	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. *International Journal of Drug Policy*, **2021**, 88, 102726	5.5	2
33	Microsimulation Model to Compare Enteral and Parenteral Iron Supplementation in Children With Intestinal Failure. *Journal of Parenteral and Enteral Nutrition*, **2021**, 45, 810-817	4.2	1
32	Carfentanil and the rise and fall of overdose deaths in the United States. *Addiction*, **2021**, 116, 1593-1599	4.6	10
31	Data Needs in Opioid Systems Modeling: Challenges and Future Directions. *American Journal of Preventive Medicine*, **2021**, 60, e95-e105	6.1	3
30	Age and generational patterns of overdose death risk from opioids and other drugs. *Nature Medicine*, **2020**, 26, 699-704	50.5	17
29	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. *Value in Health*, **2020**, 23, 734-742	3.3	20
28	A Multidimensional Array Representation of State-Transition Model Dynamics. *Medical Decision Making*, **2020**, 40, 242-248	2.5	4
27	Associations Between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes. *Pain Medicine*, **2020**, 21, 1871-1890	2.8	1
26	Computing PROPr Utility Scores for PROMIS⬚ Profile Instruments. *Value in Health*, **2020**, 23, 370-378	3.3	12
25	Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. *Value in Health*, **2020**, 23, 1534-1542	3.3	3
24	Hexamaps for Age-Period-Cohort Data Visualization and Implementation in R. *Epidemiology*, **2020**, 31, e47-e49	3.1	6

23	Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated cross-sectional data. *Health Economics (United Kingdom)*, **2020**,	2.4	3
22	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. *MDM Policy and Practice*, **2020**, 5, 2381468320932894	1.5	5
21	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. *Medical Decision Making*, **2020**, 40, 314-326	2.5	16
20	A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. *Pharmacoeconomics*, **2019**, 37, 1329-1339	4.4	14
19	"Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. *Value in Health*, **2019**, 22, 611-618	3.3	13
18	The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. *Pharmacoeconomics*, **2019**, 37, 871-877	4.4	5
17	Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. *Medical Decision Making*, **2018**, 38, 400-422	2.5	46
16	A Gaussian Approximation Approach for Value of Information Analysis. *Medical Decision Making*, **2018**, 38, 174-188	2.5	24
15	Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*, **2018**, 361,	33.3	262
14	An Overview of R in Health Decision Sciences. *Medical Decision Making*, **2017**, 37, 735-746	2.5	53
13	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. *Pharmacoeconomics*, **2017**, 35, 1073-1085	4.4	6
12	Forecasting Trends in Disability in a Super-Aging Society: Adapting the Future Elderly Model to Japan. *Journal of the Economics of Ageing*, **2016**, 8, 42-51	1.5	35
11	Forecasting Trends in Disability in a Super-Aging Society: Adapting the Future Elderly Model to Japan **2016**,		1
10	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. *Arthritis Care and Research*, **2016**, 68, 1751-1757	4.7	21
9	Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses. *Medical Decision Making*, **2016**, 36, 927-40	2.5	15
8	Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. *Journal of the American Heart Association*, **2015**, 4,	6	7
7	Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. *Medical Decision Making*, **2015**, 35, 584-95	2.5	33
6	Linear regression metamodeling as a tool to summarize and present simulation model results. *Medical Decision Making*, **2013**, 33, 880-90	2.5	32

5	Network meta-analysis of margin threshold for women with ductal carcinoma in situ. *Journal of the National Cancer Institute*, **2012**, 104, 507-16	9.7	96
4	Including indirect medical care costs from survivor years of life in economic evaluations. *Pharmacoeconomics*, **2011**, 29, 173-4	4.4	1
3	Hexamaps for Visualizing Age-Period-Cohort Data Trends		2
2	A Multidimensional Array Representation of State-Transition Model Dynamics		1
1	Predicting the impact of low influenza activity in 2020 on population immunity and future influenza season in the United States		4